Boundless Bio, Inc. (BOLD) Key Metrics
BOLD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $54.1M
- Enterprise value
- −$11.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.47
BOLD key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBOLD valuation Price multiples at each fiscal year-end price.
BOLD returns How much profit the business earns on the capital it uses.
BOLD per-share figures Results divided by the shares outstanding at year-end.
BOLD financial health Debt, liquidity and how easily interest is covered.
BOLD efficiency & capital use Working capital cycle and where the cash goes.
BOLD valuation history
BOLD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BOLD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BOLD cash returned to shareholders
BOLD price vs earnings per share
BOLD key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $26.8M | $49.3M | — | — | — | — | — | — |
| Enterprise value | −$31.7M | −$55.2M | — | — | — | — | — | — |
| Price / book | 0.3 | 0.3 | — | — | — | — | — | — |
| Earnings yield | −216.9% | −132.7% | — | — | — | — | — | — |
| Free cash flow yield | −175.9% | −128.7% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | — | — | — | — | — | — |
| Share price at fiscal year-end | $1.20 | $2.90 | — | — | — | — | — | — |
| Per share | ||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.60 | −$3.85 | −$2.22 | −$2.06 | −$1.13 | −$2.93 | −$3.40 | −$5.59 |
| Operating cash flow per share | −$2.09 | −$3.58 | −$2.11 | −$1.78 | −$1.05 | −$2.45 | −$3.18 | −$4.59 |
| Free cash flow per share | −$2.11 | −$3.73 | −$2.14 | −$1.83 | −$1.14 | −$2.72 | −$3.46 | −$6.15 |
| Cash per share | $4.81 | $8.96 | $5.43 | $3.00 | $3.28 | $9.41 | $5.03 | $9.83 |
| Book value per share | $4.41 | $8.87 | −$5.71 | −$3.67 | −$1.72 | $10.06 | $5.89 | $11.18 |
| Tangible book value per share | $4.41 | $8.87 | −$5.71 | −$3.67 | −$1.72 | $9.79 | $5.45 | $10.09 |
| Capex per share | $0.02 | $0.15 | $0.03 | $0.05 | $0.09 | $0.26 | $0.28 | $1.56 |
| Debt per share | $2.19 | $2.80 | $0.10 | $0.23 | $0.02 | $0.16 | $0.27 | $0.26 |
| Shares outstanding | 22.4M | 17.0M | 22.2M | 22.2M | 22.2M | 44.0M | 26.6M | 10.7M |
| Change in shares outstanding | +31.7% | −23.6% | 0.0% | 0.0% | −49.5% | +65.7% | +149.0% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −46.7% | −554.9% | — | — | — | −43.0% | −65.4% | −50.0% |
| Return on invested capital (ROIC) | −116.4% | — | — | — | — | −323.2% | −310.5% | −275.2% |
| Return on assets (ROA) | −32.0% | −38.9% | −47.8% | −48.2% | −8.6% | −39.6% | −56.3% | −42.0% |
| Return on tangible assets | −37.1% | −31.7% | −38.1% | −59.7% | −22.2% | −27.9% | −54.0% | −45.7% |
| Financial health | ||||||||
| Total debt | $49.0M | $47.6M | $2.2M | $5.2M | $377,000 | $7.1M | $7.2M | $2.8M |
| Cash & short-term investments | $107.6M | $152.1M | $120.8M | $66.7M | $73.0M | $414.3M | $133.6M | $104.9M |
| Net debt | −$58.5M | −$104.5M | −$118.6M | −$61.5M | −$72.7M | −$407.2M | −$126.4M | −$102.1M |
| Debt / equity | 0.50 | 0.32 | — | — | — | 0.02 | 0.05 | 0.02 |
| Debt / assets | 0.31 | 0.23 | 0.02 | 0.07 | 0.00 | 0.01 | 0.04 | 0.02 |
| Current ratio | 8.74 | 18.98 | 13.27 | 8.80 | 19.28 | 17.60 | 7.74 | 8.63 |
| Quick ratio | 8.74 | 18.98 | 13.27 | 8.80 | 19.28 | 17.60 | 7.74 | 8.63 |
| Working capital | $97.1M | $146.3M | $114.8M | $60.3M | $70.7M | $395.9M | $119.3M | $95.9M |
| Invested capital | $40.1M | $46.2M | −$245.6M | −$143.2M | −$110.8M | $35.5M | $30.2M | $17.2M |
| Tangible asset value | $98.7M | $150.6M | −$127.1M | −$81.7M | −$38.2M | $431.1M | $145.0M | $107.7M |
| Net current asset value | $51.2M | $98.6M | −$132.8M | −$90.5M | −$77.3M | $390.0M | $114.9M | $85.8M |
| Graham net-net per share | $2.20 | $5.67 | −$6.13 | −$4.13 | −$3.55 | $8.73 | $4.20 | $7.70 |
| Capital allocation | ||||||||
| Share buybacks (net) | $0 | $0 | — | — | — | $144.3M | $39.0M | $36.4M |
| Capex / depreciation | 0.44 | 2.34 | 0.66 | 1.13 | 2.98 | 1.56 | 2.01 | 10.55 |
| Efficiency | ||||||||
| Days payables outstanding | 403.4 | 587.5 | 691.1 | 479.9 | 2,461.3 | — | — | — |
| Payables turnover | 0.90 | 0.62 | 0.53 | 0.76 | 0.15 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $1.4M | $1.7M | $1.8M | $1.2M | $4.6M | $6.0M | $3.1M | $2.4M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.5% | 6.5% | 8.2% |
Computed from BOLD's annual financial statements (latest annual report filed March 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BOLD valuation and financial ratios
Boundless Bio earned a return on equity of −46.7% and a return on invested capital of −116.4% in fiscal 2025. It ended the year with $49.0 million of debt and $107.6 million in cash and short-term investments, a net cash position of $58.5 million. The share count rose 109.5% from 10.7M to 22.4M over 7 years.
See the BOLD income statement, the BOLD chart for price history, or the BOLD stock overview for the latest quote and news.
BOLD key metrics FAQ
What is Boundless Bio's return on equity?
Boundless Bio's return on equity (ROE) was −46.7% in fiscal 2025: net income of -$58.2 million on average shareholders' equity of $124.6 million.
What is Boundless Bio's ROIC?
Boundless Bio's return on invested capital was −116.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Boundless Bio have?
Boundless Bio had total debt of $49.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.50 and more cash than debt.
What is Boundless Bio's free cash flow yield?
Boundless Bio generated -$47.2 million of free cash flow in fiscal 2025, a free cash flow yield of −175.9% on its market value at year-end ($26.8 million).
What is Boundless Bio's current ratio?
Boundless Bio's current ratio was 8.74 at the end of fiscal 2025: current assets were 8.74 times current liabilities.